Table 1.
General characteristics
| Variable | Total population (n = 69) | Propofol group (n = 34) | Midazolam group (n = 35) | P-value |
|---|---|---|---|---|
| Male gender (n, %) | 45 (65.2) | 20 (58.8) | 25 (71.4) | .272 |
| Age (years) | 66.5 ± 12.0 | 67.9 ± 12.6 | 65.1 ± 11.4 | .322 |
| BMI (kg/m2) | 28.5 ± 5.2 | 28.0 ± 3.6 | 29.1 ± 6.1 | .713 |
| Hypertension (n, %) | 49 (71.0) | 26 (76.5) | 23 (65.7) | .325 |
| Diabetes (n, %) | 7 (10.1) | 4 (11.8) | 3 (8.6) | .660 |
| Dyslipidaemia (n, %) | 28 (40.6) | 13 (38.2) | 15 (42.9) | .696 |
| Smoking habit (n, %) | 16 (23.2) | 7 (20.6) | 9 (25.7) | .614 |
| COPD (n, %) | 14 (20.3) | 7 (20.6) | 7 (20.0) | .321 |
| CRI (n, %) | 4 (5.8) | 3 (8.8) | 1 (2.9) | .289 |
| Thyroid disorders (n, %) | 13 (18.8) | 6 (17.6) | 7 (20.0) | .319 |
| CHA2DS2-VASc score (median, 1st-3rd) | 2 (1–3) | 3 (2–3) | 2 (1–3) | .649 |
| Haemoglobin (g/dl) | 13.6 ± 3.3 | 13.5 ± 3.1 | 13.7 ± 3.7 | .806 |
| eGFR (ml/min) | 85.7 ± 33.6 | 83.4 ± 37.3 | 88.0 ± 29.7 | .581 |
| Sodium (mEq/l) | 134.2 ± 29.1 | 135.3 ± 24.4 | 133.0 ± 33.4 | .749 |
| Potassium (mEq/l) | 4.0 ± 1.0 | 4.0 ± 0.9 | 3.9 ± 1.0 | .696 |
| BNP (pg/ml) | 257.2 ± 86.4 | 245.4 ± 71.5 | 269.2 ± 99.9 | .276 |
| Type of heart disease: | ||||
| Hypertensive | 40 (58.0) | 19 (55.9) | 21 (60.0) | .729 |
| Ischemic | 11 (15.9) | 7 (20.6) | 4 (11.4) | .298 |
| Valvular | 5 (7.2) | 3 (8.8) | 2 (5.7) | .618 |
| Idiopathic dilatative | 2 (2.9) | 1 (2.9) | 1 (2.8) | .486 |
| Lone AF | 11 (15.9) | 4 (11.8) | 7 (20.0) | .350 |
| Echographic characteristics: | ||||
| LAD (mm) | 29.6 ± 18.1 | 30.4 ± 19.0 | 29.0 ± 17.3 | .749 |
| LVEDD (mm) | 49.2 ± 8.7 | 49.3 ± 7.7 | 49.2 ± 9.8 | .965 |
| LVESD (mm) | 30.1 ± 6.4 | 30.4 ± 6.4 | 31.6 ± 6.4 | .487 |
| LVEF (%) | 44.4 ± 15.0 | 44.7 ± 14.9 | 44.2 ± 15.4 | .930 |
| AAD at enrolment: | ||||
| Flecainide (n, %) | 15 (22.7) | 7 (21.9) | 8 (23.5) | .873 |
| Propafenone (n, %) | 4 (6.1) | 2 (6.2) | 2 (5.8) | .933 |
| Amiodarone (n, %) | 5 (7.6) | 3 (9.4) | 2 (5.9) | .592 |
| β-blockers (n, %) | 31 (47.0) | 15 (46.9) | 16 (47.1) | .988 |
| CCBs (n, %) | 18 (27.3) | 10 (31.3) | 8 (23.5) | .482 |
| Anti-platelet (n, %) | 15 (21.7) | 7 (20.6) | 8 (25.0) | .669 |
| Anticoagulant (n, %) | 52 (75.4) | 26 (76.5) | 26 (74.3) | .869 |
| Previous AF episodes (median, 1st-3rd) | 2 (1–3) | 2 (0–3) | 2 (1–3) | .353 |
| Previous DCC (median, 1st-3rd) | 0 (0–1) | 0 (0–2) | 0 (0–1) | .267 |
| Previous PC (median, 1st-3rd) | 0 (0–1) | 0 (0–1) | 0 (0–1) | .844 |
AAD Anti-arrhythmic drug, AF Atrial fibrillation, BMI Body mass index, BNP Brain natriuretic peptide, CCB Calcium channel blocker, COPD Chronic obstructive pulmonary disease, CRI Chronic renal impairment, DCC Direct-current cardioversion, eGFR Estimated glomerular filtration rate, LAD Left atrial diameter, LVEDD Left ventricular end-diastolic diameter, LVESD Left ventricular end-systolic diameter, LVEF Left ventricular ejection fraction, PC Pharmacological cardioversion